Vasoconstriction produced by hallucinogens on isolated human and sheep umbilical vasculature.
D000109:Acetylcholine / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D006213:Hallucinogens / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008635:Mescaline / Q000494:pharmacology; D011562:Psilocybin / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D012756:Sheep; D013565:Sympatholytics / Q000494:pharmacology; D014309:Tripelennamine / Q000494:pharmacology; D014469:Umbilical Arteries / Q000187:drug effects; D014470:Umbilical Cord / Q000098:blood supply / Q000187:drug effects*; D014471:Umbilical Veins / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D006213:Hallucinogens; D013565:Sympatholytics; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D011562:Psilocybin; D012701:Serotonin; D014309:Tripelennamine; D001285:Atropine; D008238:Lysergic Acid Diethylamide; D000109:Acetylcholine; D008635:Mescaline; D001920:Bradykinin; D004837:Epinephrine